Company: ZLAB
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001628280-25-023411
Chunk: 43

Company: Zai Lab Ltd
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 43
---
 activities. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. 

18. Segment Information 

The Company operates as a single operating segment that is engaged in discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. A global research and development organization and a supply chain organization discover, develop, manufacture, and supply our products. A global commercial organization markets, distributes, and sells the products. The business is also supported by global corporate staff functions. The Company’s CODM is the Chief Executive Officer, who assesses performance and allocates resources based on the significant expenses and net income on a consolidated basis. The significant expenses that are regularly provided to the CODM include those amounts that are also reported on the consolidated statement of operations as well as below additional disaggregated measures. The CODM also reviews cash position (which are cash and cash equivalents, current restricted cash, and short-term investments) that are also reported on the consolidated balance sheets when making operating decisions. In accordance with ASC 280, the Company has only one reportable segment.The following tables present disaggregated expenses that are regularly provided to the CODM:Three Months Ended March 31,20252024Personnel compensation and related costs24,079 28,008 Licensing fees19,997 — CROs/CMOs/Investigators expenses9,830 19,904 Other costs6,823 6,733 Total research and development expenses60,729 54,645 

15

Zai Lab Limited Notes to the unaudited condensed consolidated financial statements 

Three Months Ended March 31,20252024Clinical programs28,092 18,788 Pre-Clinical programs3,314 2,049 Unallocated research and development expenses29,323 33,808 Total research and development expenses60,729 54,645 Three Months Ended March 31,20252024Personnel compensation and related costs40,643 45,894 Other costs22,779 23,300 Total selling, general, and administrative expenses63,422 69,194 Three Months Ended March 31,20252024Selling and marketing expenses41,939 43,594 General and administrative expenses21,483 25,600 Total selling, general, and administrative expenses63,422 69,194 

16